Sophie Wildsmith
Executive Director, Head of PMB Immuno-Oncology (IO) Franchise AstraZeneca
Seminars
Wednesday 1st April 2026
PD-L1 as a Biomarker for Immunotherapy; Imperfect but Important
12:00 pm
- Reflecting on the immuno-oncology Dx landscape
- Discussing challenges for integrating CDx in immuno-oncology trials
- Navigating what’s next for immunotherapy CDx?
